Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and Sotorasib in KRASG12C Mutated Advanced NSCLC
NCT06249282Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Apr 2024
- Primary completion
- Nov 2026
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in non-small cell lung cancer (NSCLC), sponsored by City of Hope. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Incidence of grade 3 and 4 treatment-related toxicities. Started Apr 2024; status: recruiting.
02
Drugs
carfilzomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06249282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249282.